Miners Face Increased Risk of Rheumatoid Arthritis

Save

Add "hard rock" mining to the list of occupations associated with high rates of rheumatoid arthritis (RA), a new study indicated, with silica exposure the presumed malefactor.

CRTAC1- a Novel Biomarker for Osteoarthritis

Save

Scientists at deCODE genetics a subsidiary of Amgen report in Arthritis & Rheumatology that a novel plasma protein (cartilage acidic protein-1; CRTAC1) is a potential biomarker of osteoarthritis (OA) through its association with OA risk and progression to joint replacement.

Primer on Clinical Trials

Save

In this week's special podcast, Dr. Jack Cush offers a primer on rheumatology clinical trials, answering the question: should you be involved in research and clinical trials in rheumatology?

Predicting Cardiovascular Events in SLE

Save

A study from the Georgia Lupus Registry shows that systemic lupus erythematosus patients are at greatest risk for cardiovascular disease events between years 2 and 11 after diagnosis and higher in Black people or those with a discoid rash.

Second Efforts in Treating RA Partial Responders

Save

The results of a treat-to-target (T2T) combination therapy trial in patients with early rheumatoid arthritis (RA) show that if patients fail to respond initially, then a second, more intensified regimen can turn initial nonresponders into responders.

ACR Announces 2022 Award Recipients

Save

The American College of Rheumatology (ACR) and the Association of Rheumatology Professionals (ARP) proudly recognizes the recipients of its 2022 Master of the ACR and ARP designations, ACR Awards of Distinction, and ARP Awards of Merit and Appreciation.

Good Outcomes with TNF Blocker Use During RA Pregnancies

Save

A prospective cohort study of treatment and pregnancy outcomes in women with RA shows that TNF inhibitor use during pregnancy did not increase the risk of adverse pregnancy outcomes, but instead led to more positive outcomes such as fewer low-birth-weight deliveries.

No Special Heart Risk With JAK Inhibitors, Study Finds

Save

Patients taking Janus kinase (JAK) inhibitors for rheumatoid arthritis experienced similar cardiovascular outcomes as those using the tumor necrosis factor (TNF) blocker adalimumab (Humira), analysis of French national registry data indicated.

Intravenous Immune Globulin in Dermatomyositis

Save

Few drugs have been studied well in the treatment of dermatomyositis (DM) and only recently has intravenous immune globulin (IVIG) been granted FDA approval for the treatment of DM, based on this pivotal trial.

Tofacitinib shows promise in scleroderma

Save

Systemic sclerosis is one of the rarest autoimmune diseases, affecting roughly 100,000 people (primarily women) in the U.S. With no licensed treatments available for this subset of scleroderma patients, rheumatology researchers are searching for opportunities to use resources and technology that have proven beneficial in treating other autoimmune and rheumatic diseases.

RheumNow Podcast – “That’s Not My Name” (10.7.2022)

Save

Dr. Jack Cush goes off on "Untitling" (not using proper names/titles) in the clinic, in addition to reports on rheumatologist salaries, new drugs in phase 1-3 development and the range of COVID-19 MSK symptoms -- all from the past week on RheumNow.com.

Physician Burnout Rising

Save

The NY Times has reported results of a study showing that nearly two-thirds of doctors are experiencing at least one symptom of burnout, with a marked increase since the onset of the pandemic.  These findings suggest that burnout rates amongst US doctors have risen to alarming levels.